Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4(+) T cell interleukin-2 secretion

Therapeutic antibodies sometimes elicit anti-drug antibodies (ADAs) that can affect efficacy and safety. Engineered antibodies that contain artificial amino acid sequences are potentially highly immunogenic, but this is currently difficult to predict. Therefore, it is important to efficiently assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Arata, Yoshiyuki, Motoyama, Shigeki, Yano, Mariko, Ikuno, Tatsuya, Ito, Shunsuke, Matsushita, Tomochika, Takeiri, Akira, Nishito, Yukari, Yabuki, Nami, Mizuno, Hideaki, Sampei, Zenjiro, Mishima, Masayuki, Honda, Masaki, Kiyokawa, Jumpei, Suzuki, Hiromi, Chiba, Shuichi, Tabo, Mitsuyasu, Kubo, Chiyomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494738/
https://www.ncbi.nlm.nih.gov/pubmed/37682072
http://dx.doi.org/10.1080/19420862.2023.2253570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494738/
https://www.ncbi.nlm.nih.gov/pubmed/37682072
http://dx.doi.org/10.1080/19420862.2023.2253570

Ejemplares similares